| 4.72 -0.05 (-1.05%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.92 | 1-year : | 11.21 |
| Resists | First : | 7.64 | Second : | 9.6 |
| Pivot price | 4.96  |
|||
| Supports | First : | 4.47 | Second : | 3.71 |
| MAs | MA(5) : | 4.69  |
MA(20) : | 5.27 |
| MA(100) : | 12.49 |
MA(250) : | 384.78 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 16.9 |
D(3) : | 12.9 |
| RSI | RSI(14): 29.6 |
|||
| 52-week | High : | 2671.19 | Low : | 4.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELAB ] has closed above bottom band by 32.5%. Bollinger Bands are 80.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 173 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.78 - 4.81 | 4.81 - 4.84 |
| Low: | 4.58 - 4.61 | 4.61 - 4.64 |
| Close: | 4.67 - 4.72 | 4.72 - 4.77 |
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Tue, 25 Aug 2026
Two muscle-preserving candidates may be tested on mice in space under PMGC's proposal - Stock Titan
Fri, 10 Jul 2026
ELAB Stock Pops As PMGC Streamlines Aerospace And Expands Biotech Bets - StocksToTrade
Fri, 10 Jul 2026
PMGC Holdings Stock Surges Over 37% Overnight - PMGC Holdings (NASDAQ:ELAB) - Benzinga
Mon, 06 Jul 2026
PMGC folds two aerospace machine shops into one operating unit - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 764190 (%) |
| Held by Institutions | 5.6 (%) |
| Shares Short | 81 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -290 % |
| Return on Assets (ttm) | -33 % |
| Return on Equity (ttm) | -105.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.18 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 830.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -4.72 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 16.87 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 26590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|